Hepatology Search
Hepatology Hepatology
intrahepatic%20cholestasis
INTRAHEPATIC CHOLESTASIS
Cholestasis is bile formation and/or bile flow impairment that manifests as fatigue, pruritus and jaundice.
It can be classified into intrahepatic or extrahepatic cholestasis.
Extrahepatic cholestasis develops from mechanical blockage in the duct system or hepatocellular defects.
Intrahepatic cholestasis may be due to functional defects hepatocellularly or from obstructive lesions of the intrahepatic biliary tract distal from the bile canaliculi.

Follow Up

  • In patients with PSC, suspect cholangiocarcinoma if with weight loss, worsening cholestasis, elevated serum level of CA 19-9, and/or new or progressive stricture, especially with an enhancing mass lesion 
  • Follow-up in ICP patients should be long enough to ensure a normalization of LFTs, and it is reasonable to check LFTs at 6 weeks
    • If after 6 months there is no improvement, further specialist input will be required 
  • ICP should settle spontaneously following delivery
  • The outcome of drug-induced cholestasis after withdrawal of the drug is generally good and few patients who develop DILI show abnormal liver tests and persistent histological evidence of liver damage at follow-up
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Sodium thiosulfate may prevent cisplatin-induced hearing loss
Roshini Claire Anthony, 17 Jul 2018

Administering sodium thiosulfate 6 hours after cisplatin therapy almost halved the incidence of hearing loss in children with hepatoblastoma, according to results of the phase III SIOPEL 6* trial.
Direct-acting antivirals do not raise HCC risk in hepatitis C patients
22 Jul 2018
In patients with advanced hepatitis C infections, taking direct-acting antivirals (DAAs) does not increase the risk of subsequent hepatocellular carcinoma (HCC), a recent study has shown.
Warfarin use after LGIB-related hospitalization does not increase risk of mortality
02 Jul 2018
Resumption of warfarin at discharge following hospitalization for lower gastrointestinal bleeding (LGIB) is not associated with either 90-day or 6-month mortality, reports a study, adding that death in LGIB is primarily caused by age and comorbidities.
CPAP attenuates severity of nonalcoholic fatty liver disease in children
02 Jul 2018
Treating sleep apnoea/nocturnal hypoxia in children using continuous positive airway pressure (CPAP) appears to improve the severity of nonalcoholic fatty liver disease, according to a recent study.